Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins
about
From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaHistone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemiaMurine models to evaluate novel and conventional therapeutic strategies for cancerThe cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodiesHow animal models of leukaemias have already benefited patientsOne mouse, one patient paradigm: New avatars of personalized cancer therapyInternal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic LeTargeting of leukemia-initiating cells in acute promyelocytic leukemiaVDUP1 upregulated by TGF-beta1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progressionComprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYCMutations of Chromatin Structure Regulating Genes in Human Malignancies.Modulation of p53, c-fos, RARE, cyclin A, and cyclin D1 expression in human leukemia (HL-60) cells exposed to arsenic trioxideArsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXRalpha phosphorylation.Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia.Animal models in burn research.Transcription therapy for cancer.In vivo analysis of the molecular genetics of acute promyelocytic leukemia.Arsenic trioxide, a therapeutic agent for APL.The theory of APL.Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission.Harnessing preclinical mouse models to inform human clinical cancer trials.The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.PML targeting eradicates quiescent leukaemia-initiating cells.Mzf1 controls cell proliferation and tumorigenesisMER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cellsEstablishment of a humanized APL model via the transplantation of PML-RARA-transduced human common myeloid progenitors into immunodeficient mice.The APL paradigm and the "co-clinical trial" project.Nuclear structure in cancer cells.Arsenic trioxide: an anti cancer missile with multiple warheads.In vivo analysis of the role of aberrant histone deacetylase recruitment and RAR alpha blockade in the pathogenesis of acute promyelocytic leukemia.Acute promyelocytic leukemia: a model of molecular target based therapy.A critical review of lipid-based nanoparticles for taxane delivery.Role of promyelocytic leukemia (PML) protein in tumor suppressionBerberine enhances inhibition of glioma tumor cell migration and invasiveness mediated by arsenic trioxide.Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growthEvaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies.New Strategies to Direct Therapeutic Targeting of PML to Treat CancersThe PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation
P2860
Q24605527-C0D4C1CB-4468-457C-A8FC-5540FBCA393DQ24671020-3B4DB5CA-5F1C-4147-A5F6-B1F019B76202Q24673595-339AF6D2-CE2B-470E-845D-9B3FF0891F82Q26853348-804A944E-0B69-4E5C-90B1-EE726537C3EEQ26997702-A8AB2689-508F-4DAD-A9CC-BFB2D8C0AFFAQ27023342-56A9B39A-9A3B-4848-B68E-219999DA12BAQ27853031-B27DDA8D-E4A2-413C-9161-7BD4611CF824Q28083807-4668A6C5-601A-487D-A806-F8895CBBD7F5Q28181623-A97B5324-9DBB-4FD5-A4B2-070847C16873Q33560429-DDF775E3-FE0A-4DD9-B037-77762E7D903EQ33600399-B6E24CB4-E030-4FD9-9424-0FBEF6C7934BQ33791820-E9123888-1E07-4D74-8673-6CA953CC308BQ34014502-FC7A8C93-2526-459A-88A3-65B9544C9A08Q34035750-A28A811E-8FBE-4F8D-94B3-9908E0202CC3Q34051592-DC05851F-4A35-487E-BAD9-7C41E6772A20Q34290301-6183ADB0-F474-4C25-B570-C21EF84D6360Q34405484-46AC6567-BB98-459E-BC55-F8F6922AC493Q34435492-503F6F99-3A15-4994-85D7-6578465462DFQ34435538-8BDA2D20-427A-427B-8B24-E1C006BF305CQ34435558-A46C6CDB-8467-4936-9AE7-0B0DC04088F9Q34498952-920DA89E-FCE5-4922-B5EC-6B6A02EF6518Q34548159-645E10EC-B0C2-409B-B9F2-027310D63163Q34591761-6BE6F2C0-31C0-474B-BFC5-31F6ADA81DF7Q35079716-715426B2-2479-42EB-9F42-3D327F8C9350Q35229969-58FD5E81-C572-40A8-92F7-46244A019D64Q35391634-4B225A9C-C900-4C9A-97A1-42AFA537452AQ35568084-864D63B8-527B-4604-B7A1-904E5796A840Q35877173-5B811916-6150-4B23-A45D-892785D2E8F1Q36194579-AF018675-C522-44F5-BC74-B838F86ED924Q36228502-E7882095-6191-4679-A00E-E4889E39D524Q36270144-6C04FCFC-0F0B-479A-BDA9-4072CB8469AAQ36360764-1A8AAD7C-B19E-4A96-8313-5C0542831856Q36376155-A04AC6C7-D9B6-4D97-AB7A-C1ACB5558D55Q36509566-B610119D-CA5E-4A8F-A000-82E9F5308D56Q36545726-2FF24758-488A-4462-A394-DA3C1D92B18CQ36728942-37CED5FC-D8D1-492F-B28D-2FE3D37F7A17Q36732473-5E1A6F4E-14D8-4E5A-96B6-9A5047B9EF80Q36750049-C5B21740-3FC5-487B-98F9-E31682941B3DQ36850742-EA501849-C382-4320-B3D4-05D20D850D2FQ37200691-E26622CC-4A3F-4121-BABB-37E08CEC89D5
P2860
Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Retinoic acid (RA) and As2O3 t ...... and PLZF-RARalpha oncoproteins
@ast
Retinoic acid (RA) and As2O3 t ...... and PLZF-RARalpha oncoproteins
@en
Retinoic acid (RA) and As2O3 t ...... and PLZF-RARalpha oncoproteins
@nl
type
label
Retinoic acid (RA) and As2O3 t ...... and PLZF-RARalpha oncoproteins
@ast
Retinoic acid (RA) and As2O3 t ...... and PLZF-RARalpha oncoproteins
@en
Retinoic acid (RA) and As2O3 t ...... and PLZF-RARalpha oncoproteins
@nl
prefLabel
Retinoic acid (RA) and As2O3 t ...... and PLZF-RARalpha oncoproteins
@ast
Retinoic acid (RA) and As2O3 t ...... and PLZF-RARalpha oncoproteins
@en
Retinoic acid (RA) and As2O3 t ...... and PLZF-RARalpha oncoproteins
@nl
P2093
P2860
P356
P1476
Retinoic acid (RA) and As2O3 t ...... and PLZF-RARalpha oncoproteins
@en
P2093
P2860
P304
P356
10.1073/PNAS.180290497
P407
P577
2000-08-29T00:00:00Z